<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783701</url>
  </required_header>
  <id_info>
    <org_study_id>CoCAP</org_study_id>
    <nct_id>NCT04783701</nct_id>
  </id_info>
  <brief_title>Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)</brief_title>
  <official_title>Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the presence of graft patency in single aspirin vs&#xD;
      dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute&#xD;
      coronary syndrome (ACS) treated with coronary artery bypass surgery (CABG). Follow up time is&#xD;
      12-24 months postoperatively and the patency will be evaluated with coronary computed&#xD;
      tomography angiography (CCTA)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Graft patency after CABG</measure>
    <time_frame>12-24 months</time_frame>
    <description>Defined as patency on CCTA (FitzGibbon A) without previous graft failure identified on CCTA and/or invasive coronary angio (ICA) since CABG, intention to treat (ITT) analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft patency after CABG - PP analysis</measure>
    <time_frame>12-24 months</time_frame>
    <description>Defined as patency on CCTA (FitzGibbon A) without previous graft failure identified on CCTA and/or ICA since CABG, per protocol (PP) analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft patency after CABG</measure>
    <time_frame>12-24 months</time_frame>
    <description>Defined as non-occlusion on CCTA (FitzGibbon A+B) without previous graft occlusion identified on CCTA and/or ICA since CABG, ITT analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft patency after CABG</measure>
    <time_frame>12-24 months</time_frame>
    <description>Defined as non-occlusion on CCTA (FitzGibbon A+B) without previous graft occlusion identified on CCTA and/or ICA since CABG, PP analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft patency after CABG</measure>
    <time_frame>12-24 months</time_frame>
    <description>Defined as patency on CCTA (FitzGibbon A) without graft failure identified on CCTA and/or ICA since CABG, patients on oral anticoagulants excluded, ITT (sensitivity analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft patency after CABG</measure>
    <time_frame>12-24 months</time_frame>
    <description>Defined as non-occlusion on CCTA (FitzGibbon A) without previous graft failure identified on CCTA and/or ICA since CABG, patients on oral anticoagulants excluded, PP (sensitivity analysis).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subgroup analyses</measure>
    <time_frame>12-24 months</time_frame>
    <description>Possible interactions in response to study treatment, with special focus on the following factors; age, gender, renal function, diabetes, oral anticoagulant therapy, adherence to study treatment and time from end of study medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative analyses</measure>
    <time_frame>12-24 months</time_frame>
    <description>Performed on the graft patency of internal mammary artery (IMA) in the two treatment groups, as well as if there are any differences in graft patency between different anastomoses and grafting techniques.&#xD;
Possible predictors of graft failure in general, with age, gender, diabetes, obesity, renal failure, urgency level and length of surgery, per-operative complications, number and type of graft as well as pre-operative fractional flow reserve as variables to explore.&#xD;
Gender analysis will be performed, analyzing if female gender is associated with worse prognosis post CABG, adjusting for their higher age and burden of co-morbidities.</description>
  </other_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Coronary Bypass Stenosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include patients previously included in the TACSI-trial (Dual antiplatelet&#xD;
        therapy with ticagrelor and ASA vs. ASA alone after coronary artery bypass grafting in&#xD;
        patients with acute coronary syndrome) . This means patients with age ≥18 years that has&#xD;
        undergone for the first time an isolated CABG due to an episode of an acute coronary&#xD;
        syndrome (ACS) event within 6 weeks before CABG. The randomized, controlled trial TACSI&#xD;
        (ClinicalTrials.gov NCT03560310) offers a unique possibility to address the issue of graft&#xD;
        patency based on antiplatelet strategy in patients with acute coronary syndromes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously included in TACSI-trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Highly irregular heart rhythm (i.e. atrial fibrillation)&#xD;
&#xD;
          -  Chronic kidney disease with estimated glomerular filtration rate (eGFR)&#xD;
             &lt;45ml/min/1,73m2&#xD;
&#xD;
          -  Body weight &gt;120 kg&#xD;
&#xD;
          -  Previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based&#xD;
             contrast agents&#xD;
&#xD;
          -  Not able to communicate&#xD;
&#xD;
          -  Not willing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonas Holm, MD, PhD</last_name>
    <phone>+46101034498</phone>
    <email>jonas.holm@regionostergotland.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sofia Sederholm Lawesson, MD, PhD</last_name>
    <phone>+461037472</phone>
    <email>sofia.sederholm.lawesson@regionostergotland.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Linköping</name>
      <address>
        <city>Linköping</city>
        <state>Östergötland</state>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Holm, MD,PhD</last_name>
      <phone>+46101034498</phone>
      <email>jonas.holm@regionostergotland.se</email>
    </contact>
    <contact_backup>
      <last_name>Sofia Sederholm Lawesson, MD,PhD</last_name>
      <phone>+46101037472</phone>
      <email>sofia.sederholm.lawesson@regionostergotland.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Jonas Holm</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Coronary bypass surgery</keyword>
  <keyword>Coronary computed tomography angiography</keyword>
  <keyword>Antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

